Status:
COMPLETED
Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691
Lead Sponsor:
Pfizer
Conditions:
Hepatitis C Virus
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of PF-04878691.
Eligibility Criteria
Inclusion
- Healthy male and/or female subjects between the ages of 18-55, inclusive.
- Body Mass Index (BMI) of 18-30 kg/m2; total body weight \>50kg (110lbs).
Exclusion
- Pregnant or nursing females.
- Females of child-bearing potential.
- Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, allergic or autoimmune disease or clinical findings at screening.
- Smoking within the previous 6 months.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00810758
Start Date
January 1 2009
End Date
November 1 2009
Last Update
December 1 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511